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Purpose: To understand the process of discovery and decision-making for adults with the CDH1 
marker for hereditary diffuse gastric cancer (HDGC) and inherited breast cancer.  
Participants and Setting: Purposeful sampling included 20 participants; 17 adults (11 women 
and 6 men, ages 23–77) recruited through the No Stomach for Cancer organization; six 
participants were interviewed two times;with three healthcare providers also interviewed. 
Nineteen interviews were by telephone; one was in person. 
Methodological Approach: Grounded theory with constant comparison. 
Findings: The person diagnosed with the genetic marker CDH1 undergoes the decision-making 
process of Paving the way as they address this healthcare challenge. Paving the way explains the 
entry points for learning the risk, discerning testing for confirmation, choosing iterative 
individual cycles of surveillance, surgery, and ongoing adjustments postoperatively while 
normalizing to live longer.  
Implications for Nursing: Understanding the process of Paving the way explains and describes 
the nine key factors for decision-making and predicts the timing for nursing interventions for 
both post-genetic testing and pre- and postoperative assessment and planning.  
Knowledge Translation: Advocacy for the self and family is key to Paving the Way. Nursing 
has an opportunity to develop and expand the roles for navigator and counselor in the area of 
genetic testing. Patients undergoing PTG have chronic healthcare needs. Family implications for 
genetic testing require assessment beyond the individual. 




Stomach cancer is the fifth leading cause of cancer worldwide with 1,033,701 estimated 
new cases and 782,685 deaths reported in 2018 (Bray, et al., 2018). The survival rate is 
particularly poor (4%) for those diagnosed with advanced disease (No Stomach for Cancer 
[NSFC], 2019; Pernot et al., 2015). Inherited forms of gastrointestinal cancer (GC) occur in 
approximately 1–3% of adults. Hereditary diffuse gastric cancer (HDGC) is a rare form of GC 
that is difficult to detect and has a very poor prognosis (van der Post et al., 2015). HDGC is a 
germline (inheritable) cell-to-cell adhesion protein e-cadherin gene—known as CDH1—first 
discovered by a team of researchers within a native Maori family in New Zealand (Guilford et al., 
1999) and since identified in Europe, Canada, and the United.States (U.S.). (Corso, Marrelli, 
Pascale, Vindigni, & Roviello, 2012). The risk for CDH1-positive persons of developing HDGC 
is 70% (95% CI, 59–80) for men by age 80 and 56% (95% CI, 44–69) for women and, 
additionally, for women a 42% (95% CI, 23–68) risk for lobular breast cancer (BC; Kaurah & 
Huntsman, 2018). Statistical data for CDH1-related male BC remains undetermined. The average 
age of HDGC at diagnosis is 38; however, it can occur in adolescents and adults at ages 14–69 
(Hansford et al., 2015; van der Post et al., 2015). Detection of HDGC is difficult due to the 
insidious growth of the tumor, which begins underneath the lining of the stomach in poorly 
differentiated signet ring cell cancer (Onitilo, Aryal, & Engel, 2013; Pernot et al., 2015) and the 
lack of observable presenting symptoms in these patients (Hebbard et al., 2009; Mastoraki et al., 
2011; van der Post et al., 2015). 
Once a positive blood test for the CDH1 marker is determined, prophylactic total 
gastrectomy (PTG) is the recommended treatment to prevent aggressive adenocarcinoma (van 




2015). This recommendation results in additional decision-making issues related to family 
disclosure, genetic testing, and further screening. 
The CDH1-positive person, whether male or female, faces difficult decisions: (a) electing 
surveillance with endoscopy, (b) removing the entire stomach to avoid gastric cancer, (c) 
screening for BC, and/or (d) choosing a prophylactic double mastectomy to avoid BC (Hallowell, 
Badger, et al., 2016; Hallowell, Lawton, et al., 2016; Hallowell et al., 2017).  
Information is limited for how CDH1-positive persons embark on the decision-making 
process. Explicating this process could inform interventions for (a) clinical practice, (b) creating 
decision-making aids, and (c) providing needed patient and family support (Schreiber & Stern, 
2001). Therefore, the purpose of this study was to understand the process of discovery and 
decision-making for CDHI-positive adults regarding HDGC and inherited BC.  
Methods 
Participants and Setting   
The grounded theory (GT) study was conducted over one year after obtaining IRB 
approval at the study site. Purposive sampling was used to recruit participants (N = 20). 
Inclusion criteria were as follows: English-speaking CDHI-positive adults, family members at 
risk for the marker (tested or not tested), and healthcare providers (HCPs) caring for CDH1-
positive persons. Participants were recruited from the No Stomach for Cancer (NSFC, 2019) 
nonprofit organization, whose members total over 20,000, of whom a small percentage were 
positive for the CDH1 marker. Recruitment occurred via the NSFC website connected to the 
closed NSFC Facebook site by posting a study invitation, researcher contact information, and an 
IRB-approved fact sheet. Nineteen telephone and one in-person audio-recorded interviews were 




form. Per GT theoretical sampling, six participants (33.3%) were interviewed a second time 4–6 
months after the initial interview to further inform the substantive process.   
Methodological Approach 
The GT method by Glaser and Strauss (1967) and Glaser (2008) was used to develop the 
substantive theory. After consent, interviews lasted 30–90 minutes and were audio recorded. The 
semiflexible interview guide was modified and expanded in subsequent interviews as the data 
informing the substantive theory emerged.       
Data management and analysis used classic GT constant comparison of the data by 
Glaser and Strauss and Glaser (1967, 2008. First-level, open, selective, and theoretical coding, 
with memo sorting were employed for the theoretical model, which included theoretical 
sampling to increase the depth and variation (Glaser, 2008; Schreiber & Stern, 2001). Theoretical 
saturation was reached when no new information emerged as categories and their properties 
developed. The theory was created by the principal investigator from the dense verbatim data 
and the variations that explained and encircled the social and behavioral descriptions provided by 
the participants. As the theory developed, peer debriefing, various drafts, and figures of the 
process were reviewed with the committee members.  
Trustworthiness   
Trustworthiness was maintained by prolonged engagement within the interviews, 
observing at the NSFC meetings, and by second interviews of 50% of the participants. 
Triangulation of the data sources was accomplished by the NSFC website, by later reviewing 
other oncology-related grounded theories, and by constant comparison of interviews of the HCPs, 




field notes, and reflective writing (Glaser & Strauss, 2008; Lincoln & Guba, 1985). A member 
check was conducted with a 15-member review panel at the NSFC national meeting.  
The final figure of the model (see Figure 1) was reviewed additionally with two HCPs for 
goodness of fit, workability, making sense, and understanding. 
Findings 
Paving the way describes a decision-making process that leads to living longer (see 
Figure 1). Paving the way is initiated to avoid cancer to live longer through a four-stage process 
beginning with learning the risk of genetic susceptibility, discerning genetic susceptibility, then 
iteratively choosing interventions to normalizing to live longer. Nine factors were identified 
during the study: Age, Advocacy, Cancer found, Emotions, Gastric consequences, HCPs, Life 
events, Resources, and Witnessing (see Figure 2). These factors influenced the variation in the 
behavior of the participants throughout the process.  
Demographic and clinical characteristics are displayed in Table 1. The participants’ mean 
age was 50 years (range 23–77), with a majority being female (65%), White (90%), and married 
(58.8%). Over forty percent (41.1%) had a first-generation positive CDH1 marker. Surveillance 
biopsies or surgical mapping biopsies were reported. Of the 14 participants with PTG, n=7 (50%) 
were biopsied while under routine surveillance at least once prior to surgery, and n=7 (50%) 
underwent only endoscopic mapping surveillance biopsy prior to surgery. After PTG surgery, 
92.85% of the 14 PTG participants were found to have in situ (73.3%) or more advanced (13%) 
HDGC.  
Stage 1  
The first stage began with learning of genetic susceptibility for the CDH1 marker. 




(lobular or HDGC) , family members, or referral to a genetic counselor with or without 
knowledge of the risk for the marker (see Table 2; Stage 1).   
Cancer found first: The first point of entry occurred when cancer is found. A cancer 
diagnosis of the gastric tract or breast(s) was reported by four participants. As one stated, “I 
discovered that I had two lumps on one of my breasts… And a week later I had biopsy results 
come back that I had lobular BC.” Another participant shared, “I was being followed for 
esophagitis, and I had a 1-year follow-up, and on the biopsies, there were a couple of cells that 
looked like signet ring cell adenocarcinoma.” The cancer diagnosis along with the findings of 
lobular or signet ring cell cancer, a strong family history of cancer, or premenopausal BC 
prompted the HCP to order additional testing. The cancer found first entry point was rapid since 
participants were engaged in cancer treatment from the beginning. 
Family member: The second entry point appeared when the genetic mutation risk was 
communicated to participants by family members. Nine participants (4 CDH1-positive persons 
and 5 family members) encountered this entry point. Mothers and fathers had conducted family 
meetings with their children, while others reached out to siblings, and still others to more distant 
relatives. Many family members shared their own testing results, informed participants of their 
risk, and encouraged acting on this new knowledge. However, not all family members passed 
along or shared news with others; e.g., an elderly man who was overwhelmed by another serious 
family illness disengaged from sharing this new information. Another participant reported a 
family member ignoring HCP instructions to share the news with family members. When a 
CDH1-positive person is under age 30, parents often lead the communication.  
Genetic counselor: The third and last entry point of discovery occurred through the 




entry point were curious to know why their family history of cancer was so great. As one 
participant shared, “I have a strong family history of cancer. My mother was diagnosed with 
lobular BC and died before the age of 50.” Participants were referred based on a history of cancer 
through an HCP or by their own self-advocacy, insisting on a referral and testing related to a 
strong family history or a personal diagnosis of cancer. One participant’s rationale included “I 
just thought it was a good measure to take, just to make sure and find out where the lobular came 
from, no stone left unturned.” 
Stage 2 
Stage 2 began after learning the risk for the gene (see Table 2; Stage 2) in deciding to test 
or not for the gene.. Reactions to learning of genetic susceptibility were described as “unnerving,” 
“surprising,” and “unexpected.” For others, learning of the risk was consciously “denied” 
initially or persistently due to life events, like a serious family illness or an uneasiness about 
facing the risk for HDGC.  
Participants at this stage sought resources themselves or learned from others through 
peer-to-peer resources. A frequent source of information was the Internet. One participant shared 
that after speaking to the genetic counselor, “I googled it all weekend!” Participants also used 
these resources: HCPs, genetic counselors, family members, especially parents, nonprofit 
organizations like NSFC, reading peer-reviewed journal articles, and tapping into blogs and 
instant messaging of others who were CDH1-positive. Factors that influenced the testing 
decision included cancer already present, the psychological impact of not knowing, fear of 
cancer, curiosity regarding a strong family or personal history of cancer, and family-planning 




Various reasons motivated participants to test. For some, by witnessing family members 
with cancer: “I saw what my cousin had gone through”—or self-symptoms: “I was having 
heartburn for about a year”—or concern regarding a lobular BC diagnosis: “I asked for genetic 
testing.” After a positive CDH1 marker test was confirmed, a myriad of new emotions arose, 
ranging from denial: “I didn’t believe it, I didn’t understand it,” or “It’s not part of me”—or a 
delayed response: “Later that day it actually hit me.” For some, the emotions ranged from “a 
huge relief” as it answered their question, to an extreme negative feeling: “I felt that I had been 
given a death sentence.” However, not everyone decided to test for the marker. A middle-aged 
family member who chose not to test explained it this way: “I block it out of my life.”  
Once the decision was made, the speed for completing testing ranged from immediate to 
delayed. Self-advocacy was a key factor for testing referrals. Conditions for rapid testing 
included that cancer was already present, family-advocacy, and discerning reliable resources, 
such as the NSFC website and vetted social media sites. For some participants, the need to know 
the results of their personal risk for the gene was urgent due to concern for their children: “Well, 
I have two young boys, and I thought they have a 50/50 chance of getting it so I thought I’ve got 
to get it done.” For others the need for more rapid testing was due to the ending of insurance 
benefits or, as the endoscopic specialist shared, from a fear manifested in self-awareness of 
gastrointestinal symptoms. Alternatively, testing was delayed for others (see Table 3).  
Results of the testing were acknowledged immediately or questioned, the latter requiring a 
second confirmatory test as in the case of a participant who had not known of CDH1 in the 
family: “I paid for a test and had it, so I had it confirmed through a different testing company.” 
Two participants elected a second test for confirmation, while most did not. A genetic counselor 




extremely hard diagnosis to hear. Results were received by participants with various emotional 
responses from a delayed reaction to immediately laughing out loud or crying. Some reacted 
with a sense of panic, some with roiling anxiety, while others with quiet matter-of-fact 
acceptance. Emotional responses were varied: “I felt like I was hit with a Mack truck” or “I was 
doing fine until later that evening when it hit me”; when two siblings tested together: “Both my 
kids busted out laughing. They weren’t expecting both to be positive.” For those diagnosed with 
BC first, treatment for the cancer occurred with testing for all but one participant . After the 
testing results were known, the next step was choosing interventions to address the genetic risk 
(see Table 2; Stage 3). 
Stage 3 
Stage 3 began with choosing interventions, including surveillance, surgery, or treatment 
after PTG, and/or prophylactic mastectomy (see Table 4 and Figure 3). Choosing interventions 
was individually based on the factors underlying each person’s situation at the time of discovery. 
The point of discovery influenced the order of procedures chosen; e.g., when BC was diagnosed 
first in a participant, treatment continued and was not interrupted by a positive test for the gene. 
However, some surveillance for HDGC or lobular BC might have begun prior to surgery. As one 
participant said:  
I have been doing the mammogram, and I am getting an MRI. I'm looking to next year to 
have the bilateral mastectomy, and that is a depressing factor. I mean, it's like you lose 
part of what makes you feel a woman.   
  
Emotions influenced engaging in next steps for choosing interventions were varied as 




to deal with it for the rest of their lives”—and fears surfaced about the diagnosis: “It’s so horrible 
and it’s so evil and it’s so frightening”—or the impact of witnessing others dying: “I have seen 
very young family members die from this and it was ugly and they were very, very sick”—to 
temporary denial: “The genetic counselor couldn’t possibly be saying that I have to have my 
stomach removed.” Two participants doubting their results retested and were informed of the 
same results with the second testing  
Choosing interventions included, PTG, esophagogastroduoendoscopy (EGD), or breast 
surveillance, or chemotherapy. Treatments were influenced by age, self/family advocacy, cancer 
found, generational concerns, HCPs, psychological impact, resources for decision-making, and 
witnessing. Participants chose interventions sequentially, such as an EGD followed by PTG, 
including preoperative planning. At times, either treatment, surveillance, or surgery was 
warranted or required postoperatively, such as PTG dilatation of the GI tract, dumping syndrome, 
or relief from an obstruction.  
One factor shared by some participants at this stage involved needing to make a rapid 
decision about choosing an intervention to undergo PTG after hearing about HDGC from a 
family member, when witnessing a family member diagnosed with HDGC, or knowing persons 
having surgery to rapidly remove the risk for cancer. For example, nine participants, who had 
witnessed family members dying from stomach or breast cancer or witnessed another with the 
CDH1 gene, immediately elected PTG surgery to avoid cancer rather than running any further 
risk by delaying this intervention. Two participants also considered prophylactic double 
mastectomy soon after the PTG because of a strong history of familial BC. 
Age affected the speed by which participants decided to undergo surgery, as CDH1-




Older participants tended to wait to have surgery and would take more time to seek the opinion 
of HCPs and genetic counselors to determine whether surgery was warranted due to age and 
other existing comorbidities. Similarly, younger persons were inclined to delay interventions as 
they considered family planning age and family history of BC as factors for BC surveillance vs. 
prophylactic mastectomy and multiple endoscopic biopsies prior to PTG. For those planning or 
already raising a family during their middle 20s to early 40s, conditions that affected the timing 
of interventions included family planning, career considerations, practical issues like health and 
insurance benefits, and managing family household duties.  
Resources that helped the participant make intervention decisions included physician 
consultation, genetic counselor recommendations, peer-to-peer online sharing, communication 
with reliable bloggers, and data available at nonprofit support sites such as NSFC. Self-advocacy 
was used to obtain referrals and recommendations about where and with whom to have the PTG, 
including surgeon expertise in PTG intervention. A majority of the CDH1-positive participants 
expressed relief in obtaining access (n = 13) to travel away from home for the PTG based on the 
physician’s level of expertise. One participant shared “Because a lot of the times that's what 
happens when the people have some kind of a problem elsewhere where they had the surgery,—I 
just would rather go to the experts.” Further ability to access expert surgeons was also influenced 
by financial considerations, such as insurance coverage. 
The iterative nature of the decision process in Stage 3 would lead to Stage 4—
normalizing. After adjusting in Stage 4, the participant is often led back to Stage 3 where the 
next intervention decisions are made, leading to ongoing adjusting and additional treatment on an 




Managing the initial intervention, subsequent treatment, or additional surveillance 
described the work of participants during Stage 4. This stage harkened the beginning of 
normalizing through adjusting to the changes brought on from the interventions chosen in Stage 
3. Adjustments at Stage 4 included managing post-PTG motility modifications, surgical 
complications, dietary changes, body image adjustments, fatigue, and planning for generational 
concerns in the family, including future testing and surgery for the children and future family 
planning.  
Stage 4 
Stage 4 involves normalizing, including adjusting postoperatively. The iterative nature of 
Stage 3 and Stage 4 are related in part to the level of complexity especially when a cancer 
diagnosis was present prior to a person learning they were CDH1-positive (see Figure 1). 
Interventions were completed while new interventions would also be chosen, such as 
surveillance, surgery, or further treatment. Timing varied in both speed and order, such as how 
and when to consider surveillance for BC after completing gastric surgery with PTG, or vice 
versa in surveillance with endoscopy after undergoing a mastectomy. Such further interventions 
included PTG, double prophylactic mastectomy, endoscopic biopsies, and BC surveillance, 
including alternating MRI, ultrasound, mammography, and chemotherapy. Some participants 
reduced the layers of decision-making such as electing the PTG without surveillance biopsies. 
Other participants needed other interventions beyond monitoring the PTG adaptations, such as 
BC surveillance or deciding when to choose a prophylactic double mastectomy. After each 
intervention was chosen and completed, priority was given to adapting through follow-up and 
adjusting by monitoring. Further discussions about the timing and choice of additional surgical 




leading back to Stage 3. A participant who was 6 months post-PTG was considering where to 
have her double prophylactic mastectomy and noted this: “So (not being alone again) was a big 
deciding factor with changing the location and having it (mastectomy) done here at my 
hometown at one of the local universities.” 
Physical changes and gastric complications were reported after PTG (see Figure 4). 
Weight loss was a common response. One participant noted, “I'm struggling to put weight back 
on, but that's also fairly normal.” Two participants spoke of looking in the mirror with sadness 
regarding skin turgor or muscle mass changes. Social challenges were reported most especially 
in public situations where others might watch how much or what they eat, comments about their 
change in body type, and having their PTG compared to bariatric surgery for obesity. 
Psychological adjustments ranged from “not a big deal” and “I feel so tired” to “I just want to 
feel like myself again.” 
Two participants reported a few adjustments to the PTG but were more concerned and 
dreading the next set of decisions regarding breast health and cancer risk. Emotional support was 
critical throughout Stage 4, including HCP listening, peer-to-peer support on the Internet through 
social media, and personal counseling sought by a few. One participant, when asked about any 
advice during the adaptation phase of her surgery, shared her approach as “It's really more of a 
mental game than the actual physical because the physical is something you can't really change.” 
Physical comparison before and after PTG was noted by one participant:  
I couldn't even physically open the hospital door because the door seemed heavy. And 
I'm just not used to… like normally I’d be “Hey I got that!” I would be strong; I'd be the 




Another participant also indicated, “One of the things I have learned is that I have to be a really 
good advocate for myself.”  
Self-advocacy after PTG included informing HCPs about which oral medications were 
tolerable or malabsorbed without a stomach, such as iron or B12. An older participant described 
the new rebalancing after PTG: “My iron was running a tiny bit low. The B12 was running low. 
The D was running a little low. I take supplements for all of those.... They’re now all within the 
normal range.” The length of the adjustment period varied for participants to adopt a new diet, 
smaller more frequent meals, and social situations involving intolerance to food.  
Resources for learning what was expected pre- and post-procedure were identified 
consistently within distant specialty centers, sometimes locally, and often through peer-to-peer 
online support. As in Stage 3, participants sought others who had similar issues or experience. 
Participants were often managing multiple issues during Stage 4, such as caring for a family 
while undergoing treatment, seeking a nutritionist or registered dietician, family-planning 
considerations. They solved their challenges in this stage by reaching out for practical health and 
psychological support with peer-to-peer social media, including internet bloggers, while others 
sought traditional support groups and attended meetings, such as the NSFC Spotlight events. 
Overall, the four stages revealed that Paving the way is a complex process that accounts for 
individual conditions, contexts, factors, and influences leading to living longer. 
Implications for Nursing 
This GT study adds to the body of nursing knowledge through describing a substantive 
theory informing decision-making at each stage for those diagnosed with the CDH1 marker. The 
substantive theory provides nurses a roadmap for the patient diagnosed with the CDH1 marker to 




be utilized in further testing of influences and conditions as interventions to ameliorate anxiety 
and fears while inform patients better throughout the different stages of decision-making for the 
patient and the family after the diagnosis of the CDH1 marker. Nurses may assess for self/family 
advocacy, shared decision-making needs, resources such as peer to peer support, and navigating 
through life-event concerns within the complexity of care when cancer is found first for those 
diagnosed with the CDH1 marker. The development of a postoperative physical adjustment scale 
would also help predict further physical and emotional interventions such as managing nutrition 
and genetic risk in pregnancy and family planning. The study of influences of peer-to-peer social 
media influence is also warranted.  
Nursing assessment should occur with these patients throughout the process of pre-and 
post-procedures including management of genetic testing, treatment, surveillance, and surgical 
interventions  and post-surgical consequences.  Patients living longer through preventative 
genetic decision-making need a nurse in the role of survivorship coach and throughout the 
adjustment process with wellness navigation.  Evaluations post-operatively including appropriate 
follow-up services with specialized registered dieticians through nurse-navigation with the 
patient are essential for wellness post PTG.  
Knowledge Translation 
The findings of this study demonstratethat patients with the CDH1 marker face a 
complex process of problem-solving throughout this decision-making process including 
influences and conditions that occur from the entry point while faced throughout lifetime. The 
influences and conditions found in this study of age, advocacy, and the timing of life events 
compare to the following studies: (a) Life Course Perspective (LCP) grounded theory of Living 




pregnancy after PTG (Kaurah, Fitzgerald, Dwerryhouse, & Huntsman, 2010); (c) the predictive 
genetic testing grounded theory of Engagement (McAllister, M., 2002); and (d) the recent virtual 
model program in oncology for navigation to promote self-advocacy (Schaffer, Haag, Borazanci, 
& Von Hoff, 2019). In the LCP, age was the primary factor of focus subdividing the cohort into 
groups—timing of events (20s), human agency (30s), and linked lives (40–50s)—all of which are 
comparable to the factors of age, advocacy, and life events throughout the stages of this study.  
The findings of this study also reflect the need for persons with the CDH1 marker to 
make decisions to avoid or detect cancer early to preserve their health and have longer survival. 
Paving the way is comparable to other grounded theory research on the BRCA gene and ovarian 
cancer. Three grounded theory studies concluded that the goal of decision-making for patients 
with the BRCA syndrome included Preserving oneself (Howard, Balneaves, Bottorff, & Rodney, 
2011) and Maximizing survival (Jeffers, Morrison, McCaughan, & Fitzsimons, 2014), and, with 
patients experiencing ovarian cancer, the goal of facing a life-threatening cancer is Preserving 
oneself in the face of uncertainty (Pozzar & Berry, 2019).  
Several decisions were made throughout the process of Paving the way from the time 
participants were first made aware of their risk of having a genetic syndrome involving testing, 
undergoing procedures and/or surgery. A qualitative descriptive study of “previvors” for 
hereditary breast and ovarian cancer needed resources in four stages: pretesting, posttesting, 
premanagement, and postmanagement (Dean et al., 2017). A Norwegian grounded theory 
described that participants handled emotions while waiting for a gastric diagnosis by Preparative 
waiting that outlined a balance between “hope and despair” (Giske & Gjengedal, 2007, p. 90). 
An Australian registration study reviewing predictive testing for hereditary colorectal cancer 




the resources, benefits outweighing risks, and a need for witnessing positive outcomes over 
negative before electing testing (Keogh, Niven, Rutstein, Flander, Gaff, & Jenkins, 2017).  
This study revealed that most, but not all participants decided to share information that family 
testing was recommended. They deliberated on the timing of when and how to tell due to age, 
life events, and to whom to share with in the family, which is consistent with patterns of 
disclosure to families at risk for Huntington Disease (Klitzman, et al., 2007). This study’s finding 
of interventions and adjusting to life through normalizing compares to the grounded theory 
studies of patient survivorship after diagnosis of Hodgkin lymphoma—Transitioning to 
survivorship (Matheson et al., 2016)—and the BC survivor—Reclaiming life on one’s own terms 
(Sherman, Rosedale, & Haber, 2012)- the person adjusting to a changed life with the diagnosis of 
multiple sclerosis (Satinovic, 2017) and gaining normalcy as one re-engaged and re-invigorated 
mentally and physically after the disruption of a cancer diagnosis (Walker, R., 2015).  
Conclusion 
 The findings from this study suggest that Paving the way offers nursing greater 
understanding of the process for the person diagnosed with the CDH1 mutation. Applying the 
model will aid in navigating the layers of complexity in their decision-making..  Nurses are in a 
unique place to serve as genetic nursing counselors in high-risk oncology clinics, pre- and 
postsurgical intervention as navigators, educators, and advocates for those diagnosed with this 
rare genetic syndrome and their families. The shortage of certified genetic counselors, especially 
in rural areas, positions nursing to further develop the specialty role of the genetic-counseling 
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Table 1. Participant Demographic and Clinical Characteristics (N = 20) 
Demographic Data  Participants Family Members Healthcare 
Providers 
        
Gender  Female Male Female Male Female Male 
  N = 10 N = 2 N = 1 N = 4 N = 2 N = 1 
        
Age Range (years)  23–77 61–70 20–72 32–46 
Average Age (years)  50.7 65.5   
      
Race     
White/Caucasian  9 2 5 2 
Black/African American  0 0 0 0 
Asian  1 0 0 1 
Native Hawaiian or 
Pacific Islander 
 0 0 0 0 
American Indian/Native 
American 
 0 0 0 0 
      
Ethnicity      
Hispanic/Latino  1 0 0 0 
Hispanic/Non-Latino  9 2 5 0 
      
Marital Status      
Married  8 2 0 N/A 
Separated  0 0 0  
Single  0 0 3  
Divorced  1 0 1  
Other  1 0 1  
      





N = 6 
Second 
N = 5 
Third 
N = 3 
Fourth 
N = 1 





N = 10 
Male 
N = 2 
Female 
N = 1 
Male 
N = 2 
Family members 
who did not test 
N = 2 




1 year–>12 years  
Average  2.2 years 2 years   






Surveillance biopsy      
Yes  3 1 1 N/A 
Procedure, average 
number 
 2 2 4  
Mapping biopsy only?  7 1 2  
      
Total Gastrectomy     N/A 
Yes  10 2 3  
No  0 0 2  
      
Chemotherapy      
Yes  4 1 0  
No  7 1 0  




     
Yes  3 N/A 0  
No  7  1  
      
Screening for breast 
cancer risk? 
     
Yes  7 0  N/A 
No  0 2 3  
      
How often screening 
completed? 
     
Every 6 months  7 0 0 N/A 
Yearly  0 0 0  
Every 2 years  0 0 0  
Other  0 0 0  
      
Stomach cancer or 
in-situ cancer found 
after total 
gastrectomy? 
     
Yes  9 2 3  





Table 2. Stages, Core Category, and Accompanying Participant Narratives 
Paving the Way Decision-Making Verbatim Quotations 
Stage 1 
 




Learning of genetic 
susceptibility is 
discovered through 




Choice is to share or 
to not share the news, 
listen or not listen to 
the news.  
Entry points of 
discovery of the news 
appear via  
1. Cancer found first,  








We all got together for a big family meeting to discuss that 
she had breast cancer and that they were trying to figure out 
why it had happened. 
 
My daughter had stomach cancer and they discovered it 
down in (X healthcare facility). Her diagnosis sheet was on 
her (other daughter’s) kitchen counter, and my other 
daughter read it, and read it was hereditary diffuse gastric 
cancer. She said, hereditary? So, she looked it up and saw, 
gee is this something in the family?  
 
My mom received a phone call from a cousin from her dad’s 
side saying that they carried a gene and that she likely had 
the disease (gastric cancer) because she (the cousin) ended 
up inheriting it. 
 
I didn’t know that I was at risk. I asked to have the genetic 
testing due to my lobular breast cancer diagnosis. I was told 
I was not a candidate due to my family, no direct family 
history. I insisted upon having genetic tests, a genetic panel 
was done.  
 
I put this message out there (by social media to the family) 
because I want to keep them informed, to let them know if 
you do want to get tested, go get tested. 
 
Well, once I knew they assumed it was from my father’s 
side. I suggested to my mother, father, sister that everyone 
get tested because it is a dominant gene and hereditary. Then 
 
 28 
I contacted my second cousin and she said, “Oh, I have that 








Knowing the risk 
and confirming it. 
The process 
involves believing 
the risk exists and 






Choices are to test or 
to not test for the 
marker. 
Testing is immediate, 





Since my mother had died and my two uncles had died from 
stomach cancer. We didn’t know it was CDH1. So, then I 
went and talked to a genetic counselor on the phone. 
Well, my mother is dying of diffuse cancer, and her 
oncologist, who I thought was great, he had enough good 
sense to check her for this mutation. She found out. She told 
all of us….I did a little research on it…So I wasn’t sure what 
to do, but I thought I’ve got two young boys and we had a 
50-50 chance of getting it so I thought, well I got to get it 
done. 
I had to know. Just like, yeah, (it) sits in your head. I guess I 
felt a sense of urgency too. 
I think that I was complaining about ongoing heartburn and 
stomach issues and he (the doctor) had already known that I 
carried a risk, so he encouraged me to get tested.  
 
I put it (testing) off because for me it was more of an 
insurance issue because I wanted to make sure that my 
career and my life insurance and my disability insurance 
were in place and then I want to get a house and then have 
my mortgage and all that before I found out I may have a 
risk for cancer.  
 
He has several times spoken to his different physicians, and 
he still hasn’t had any testing. But I know he thinks about it 
from time to time. And I don’t really say anything unless he 






















Choices are to treat a 







chosen one at a time 
in a personalized 
order, immediate, or 
delayed, or not 
chosen.  
 
Stages 3 and 4 are 
iterative. Stage 3 is 
revisited and leads 
back to Stage 4 for 
each next decision in 





Proactively I can cure this if it hasn’t spread, you know, 
metastasized. 
 
It was recommended that I get my entire stomach removed. 
There were a lot of questions. When is the best time to do 
that? How will it impact my life? How will it impact having 
children?  
 
Obviously, there’s no convenient time to get your entire 
stomach removed. I have a job; my husband is still a student 
in school.  
 
My mother passed away from lobular breast cancer, and I’m 
probably going to get it (cancer) if I don’t do this 
(mastectomy).  
 
It was the internet, literally internet.com. It’s been a rough 
10-week transition. I didn’t know anything about cancer 
until it came upon me, I didn’t know anything about CDH1 
until it happened to me. But I certainly spent a lot of time 
researching and finding out what I can do to be protected, to 
help myself. 
 
For my double mastectomy because of logistics, I might 
elect to have the surgery somewhere else, because it might 
be too difficult for me to do follow-up care in (a far-off 
state). I still must sort that aspect out.  
 
He still needs to make his decision. We'll do the endoscopy; 
 
 30 
we'll see how that looks. We know, damn well, the 
endoscopy means nothing. I mean, there's cancer there, like 


























Returning to Stage 3, 





They came back and said that he did have the signet ring 
cancer cells, so he did have cancer. It was super-duper early; 
we didn't expect to find much other than that. 
 
I don’t have a stomach and that causes havoc. You’re 
starting over again with the foods.  
 
I plan my time and my energy carefully. I plan when I’m 
going to eat. 
 
You don’t have hunger. I must make myself go eat lunch. 
It’s not like suddenly, I’m starving. You don’t have that 
feeling.  
Your esophagus seems to get smaller. I have trouble 
sometimes when I’m eating, especially at dinner time. It just 
doesn’t want to go down. I used to get up and just walk 
around the room. What happens is you just get used to all of 
it. It’s not any big deal anymore.  
The second round, after major surgery and no longer having 
a stomach, it was much more difficult. So, my biggest 
adjustment, still, is I'm too skinny. I'm struggling to put 
weight back on, but that's also normal. I'm sort of just riding 
out, and saying this too shall pass, and just trying to do 









They thought of our family history (of breast cancer), annual 
MRI starting at 25, and at 30, we're (mother and daughter) 
getting MRI mammograms every 6 months, then 






Table 3. Reasons to delay or choose to not test for CDH1 vs. more rapid testing 
 
 Delayed or No Testing Rapid Testing 
Clinical No recommendation from HCP 
No GI symptoms 
HCP declined referral to test 
HCP insistence on testing 
GI symptoms 
Gastric cancer found 
Breast cancer found 





Health insurance to end new job 
Aging out of participant for 
healthcare coverage 
Psychological Serious family illness resulting in 
death 
Conscious denial 






Table 4. Participant (N = 17) CDH1 Testing and Surgical Interventions 










1 + Y N/A N/A 
2 + Y N N 
3 + N Y Y 
4 + Y N N 
5 + Y Y Y 
6 + Y N N 
7 + Y Y N/A 
8 + Y N N 
9 + Y N Y 
10 + Y N N 
11 + Y N N 
12 + Y Y Y 
13 + N N/A N/A 
14 + Y N N 
15 + Y N N/A 
16 N/A N/A N/A N/A 
17 N/A N/A N/A N/A 
Total = 17 CDH1 + = 15 PTG Y = 13 Breast = 3 
GI SRC = 1 
Total = 4 
Note. CDH1 = Cadherin-1 gene; PTG = prophylactic total gastrectomy; N/A = not applicable; Y = yes; N 











Figure 1. Paving the Way: A Grounded Theory. 
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Figure 2. Influences, Conditions, and Consequences 
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Figure 4. Normalizing and Adjusting 
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